Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Chinese Patients: A Pilot Study. (December 2013)

• Record Type: Journal Article
• Authors: Shea, Yat Fung; Chu, Leung-Wing; Zhou, Lin; Li, Wing-Man; Lin, Oi Yee; Chan, May N. Y.; Xu, Aimin; Wong, Rachel; Ho, Tip Yin; Liu, Kin Wah; Ha, Joyce; Daniel, T.W.; Song, You-Qiang; Lam, Karen S.
• Is Part Of: American journal of Alzheimer's disease & other dementias. Volume 28:Number 8(2013)
• Page Start: 769
• Page End: 775
• Publication Date: 2013-12
• Subjects: CSF -- biomarkers -- Alzheimer's disease -- Chinese; Alzheimer's disease -- Periodicals; Dementia -- Periodicals; Alzheimer's disease -- Patients -- Care -- United States -- Periodicals; 616.83
• DOI: 10.1177/1533317513504615
• Languages: English
• ISSNs: 1533-3175

Abstract

In view of the paucity of data on cerebrospinal fluid (CSF) biomarkers in Chinese patients, we evaluated the validity of tau, phosphorylated tau 181 (p-tau-181), amyloid β 42 (Aβ42), and Aβ40 proteins in Chinese patients with Alzheimer's disease (AD). We recruited 24 patients with AD, 12 nondemented controls, and 12 patients with non-AD dementia. We found the CSF levels of Aβ42, tau, p-tau, Aβ42–tau, and Aβ42–p-tau ratios, except the Aβ40 protein level, were significantly different among the 3 groups of patients. Patients with AD had higher levels of CSF tau and p-tau but lower levels of Aβ42 proteins, Aβ42–tau, and Aβ42–p-tau ratios than the nondemented controls. In the diagnosis of AD versus nondementia, the sensitivity and specificity of the ratios of Aβ42–tau and Aβ42–p-tau were 96% and 83% versus 92% and 83%, respectively. Only the Aβ42–p-tau ratio showed satisfactory sensitivity and specificity in the diagnosis of AD versus other dementia.